Trial Profile
Safety and Potential Effectiveness of Positron Emission Tomography (PET) Imaging of Patients with Low & Intermediate Grade Neuroendocrine Tumors using 64Cu-SARTATE: A Single Centre, Open-Label, Non-Randomized, Phase-0 Microdosing Investigation
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs 64Cu-MeCOSar-Octreotate (Primary) ; Gallium 68-DOTATATE
- Indications Neuroendocrine tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
- Sponsors Clarity Pharmaceuticals
- 06 Sep 2017 New trial record